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  ABSTRACT 
Absorption of proteins into cationic chitosan microparticles through 
electrostatic interaction is a common process suitable for oral delivery of 
proteinaceous drugs. In this research work, in order to achieve a good stability and 
encapsulation efficiency for an oral drug delivery system, different combinations 
chitosan, acetic acid Sodium tripolyphosphate and model protein bovine serum 
albumin were tried and formulated. Then alginate microparticles were coated with the 
BSA loaded chitosan. Morphological characterizations of the particles were done 
using zeta sizer and SEM (scanning electron microscope). It was found that Chitosan 
of 4mg/ml and 5mg/ml concentration had loading efficiency more than 60% and with 
a particle size in between 400-500 nm. Again when the particles were coated with 
alginate, the particle size increased from 1400-1600nm (1.4-1.6 μm), can be 
effectively used for oral drug delivery. In vitro release of BSA from chitosan 
microparticles and BSA loaded alginate coated chitosan particles were checked by 
taking particles at different time intervals at pH7.4 using PBS (phosphate saline 
buffer). Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
assay shows that encapsulation with chitosan and further coating with alginate could 
effectively protect BSA from degradation or hydrolysis in acidic condition for at least 
2 hours (using HCl pH 2.0). 
 
 
 
iv 
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                                                                                                  INTRODUCTION 
Oral delivery of peptides and proteins remains an attractive alternative to 
parenteral delivery and has challenged various attempts at drug delivery development. 
Incorporation of new tools into the delivery systems that can raise membrane 
permeability of macromolecules is essential to attain high oral bioavailability that is 
acceptable in clinical applications. Administering drugs orally is so far the most 
widely used route of administration, although it is generally not suitable for peptide 
and protein drugs. The main reasons for the low oral bioavailability of biological are 
presystemic enzymatic degradation and poor penetration of the intestinal membrane. 
Much has been learned in the past few decades about macromolecular drug absorption 
from the gastrointestinal (GI) tract, including the barriers that restrict GI absorption. 
Various strategies have been followed to overcome such barriers and to develop safe 
and effective oral delivery systems for proteins. Most oral delivery strategies for 
biological are based on system equipped to protect against enzymatic degradation and 
provide high transfer of drugs across the epithelial mucosa. Certain particles can be 
taken up by the Payer’s patches without employing additional penetration enhancers. 
So far, polymeric drug delivery systems based on hydrogels, nanoparticles, 
microspheres, and lipid-based drug delivery systems (e.g. micro-emulsions, 
liposomes, and solid lipid nanoparticles) have been developed and employed for oral 
macromolecular drug delivery. Natural polymers like chitosan, alginate etc. have 
caught the eyes of the pharmaceutical scientists till now for the purpose of the oral 
drug delivery due to their attractive features like non toxicity and biodegradable 
properties. Chitosan, a natural cationic polysaccharide derived from chitin is a 
copolymer of glucosamine and N-acetyl glucosamine units (Ravi Kumar, 2007), has 
gained an increased attention in biomedical as well as pharmaceutical purposes due to 
its biocompatible properties such as non-toxicity, biodegradability (George and 
Abraham, 2006 and  Gan et al., 2005), muco-adhesive properties etc. This 
biodegradable polymer is synthesised by alkaline deacetylation of chitin by the 
enzyme Chitin deacetylase as presented in figure 1. 
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Fig.1 Production of chitosan by the deacetylation of chitin by the enzyme chitin 
deacetylase. 
On the other hand Alginate (Fig.2) is an anionic polysaccharide extracted from 
brown algae, composed of α-L-guluronic acid (G) and β-D-mannuronic acid (M) 
residues, arranged in homopolymeric blocks of each type (MM, GG) and 
heteropolymeric blocks (MG) (Takka and Gruel, 2010) increase the stability of drugs 
and prevent an immediate desorption of drugs from chitosan carriers in 
gastrointestinal tract (GI) tract. 
 
                                  Fig.2 Structure of alginic acid (alginate). 
Both the polymers have been used extensively in production of pharmaceutical 
products especially for drug delivery purposes. In this paper chitosan and alginate 
were chosen due to their extensive biocompatible properties. Various authors used 
Alginate to coat over BSA loaded chitosan for maintaining stability of the drug and 
chitosan for good drug encapsulation properties. Keeping this in view we have used 
both alginate and chitosan for the formulation of drug delivery system in this work. 
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                                                                                  REVIEW OF LITERATURES 
 
Peptides and proteins have become the drugs of choice for the treatment of 
numerous diseases as a result of their incredible selectivity and their ability to provide 
effective and potent action (Frokjaer and Otzen, 2005) due to their fewer side effects 
and higher potency to cure diseases. Pharmaceutical scientists have produced variety 
of protein and peptide drugs in commercial scale using biotechnological techniques 
(Shah et al., 2002, Torchilin et al., 2003 and Frokjaer and Otzen, 2005). In recent 
years, there has been a significant increase in the number of targeting mechanisms 
available to the pharmaceutical scientist to provide site-specific delivery in the 
gastrointestinal (GI) tract (Hwang et al., 1998). Generally, it is highly beneficial to 
target a drug to a particular site within the GI tract either to maximize a therapeutic 
response or to reduce side effects caused by drug delivery to an inopportune region of 
the gut (Hwang et al., 1998 and Lee et al., 1991). Drug absorption differences in 
various gastrointestinal segments. In general, drug absorption is moderately slow in 
the stomach, rapid in the small intestine, and sharply declining in the large intestine. 
 
Compensation for changing absorption characteristics in the gastrointestinal 
tract may be important for some drugs. For example, it is rational for a delivery 
system to pump out the drug much faster when the system reaches the distal segment 
of the intestine, to avoid the entombment of the drug in the feces (Burnside, 2004). 
The instability and poor absorption of drugs in gastrointestinal tract is major obstacles 
in the development of oral drug delivery system for mucosal vaccine as well as 
protein and peptide drugs. Problems such as pre-systemic enzymatic degradation 
(Morishita and Peppas, 2006) and acid degradation in stomach, poor permeability 
across the gastrointestinal mucosa and the first-pass metabolism greatly limited the 
uptake of antigens by M-cell which is very important step for immune response 
(George and Abraham, 2006 and  Jepson et al., 2004). Thus to overcome such 
problems different strategies like liposomes (Wang, 1996; Okada et al.,1997 and 
Anderson et al., 2006), micro/nanoparticles (Vila et al., 2002; Lubben et al., 2002 and 
Lubben et al., 2003), micro/nanoemulsion (Bielinska, 2007), and etc., have been 
explored to encapsulate antigens for the mucosal vaccine.  
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In developing oral protein delivery systems with high bioavailability, three 
practical approaches might be most helpful: (1) modification of the physicochemical 
properties of macromolecules; (2) addition of novel function to macromolecules; or 
(3) use of improved delivery carriers (Morishita and Peppas, 2006).  
 
Chitosan and alginate in oral drug delivery 
In design of oral delivery of peptide or protein  drugs, one important aspect is 
that some natural polymers like alginate and chitosan (CS) have attracted increasing 
attention since most of the synthetic polymers are immunogenic and the incorporation 
of proteins into these polymers require a harsh environment which may denature and 
inactive the desired protein (George and Abraham, 2006). 
 
Chitosan(CS) micro/nanoparticles can be easily prepared by ionic gelation 
method using tripolyphosphate (TPP) as precipitating agent (Gan et al., 2005).In spite 
of all superior qualities like non-toxicity, biodegradability etc. chitosan has an 
apparent pKa of 5.6 and is only soluble in acidic solutions. When incubated in 
physiological fluid environment, chitosan will lose its capacity of mucoadhesive 
properties and permeation enhancing effect due to the de-protonation of chitosan, 
which would make chitosan carriers lose its advantage compared with other carriers 
for mucosal vaccine (Xing et al., 2008).  
 
There are numerous factors affecting the relevant properties of the alginate–
chitosan capsules (George & Abraham, 2006). Among these factors are the 
composition, molecular weight and deacetylation degree of chitosan (Alsarra et al., 
2002). While pure CS is soluble in low pH and insoluble in higher pH, alginate shows 
the opposite trend. Upon mixing, the ammonium groups of chitosan and the 
carboxylate groups of alginate ionically interact to form the polyelectrolyte complex. 
Complexation of chitosan with alginate reduces the porosity of gels and decreases the 
leakage of the encapsulated drugs. The solubility of chitosan at low pH is reduced by 
the alginate network since alginate is insoluble under low pH conditions, and the 
possible dissolution of alginate at high pH is reduced by chitosan which is stable at 
high pH ranges (George and Abraham, 2006). So a stable rigid drug delivery matrix  
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of the alginate–CS polyelectrolyte complex can be produced by the 
electrostatic interaction between the carboxyl groups of alginic acid and amino groups 
on CS, which can protect the drug from the harsh acidic environment of the stomach 
(Wittaya-areekul et al., 2006; Gotoh et al., 2004; Sezer and Akbuga, 1999; Tapia et 
al., 2007 and Takka and Gruel, 2010).  
 
Chitosan could enhance the immunogenicity of poor immune response 
antigens in the form of solution and micro/nanoparticles (Zaharoff et al., 2007 and 
Amidi, 2007). Among the various natural polymers available, chitosan (CS) is 
perhaps one of the most widely used biopolymers for the preparation of nanoparticles 
(Allemann, 1998). Absorption of antigens onto chitosan microparticles via 
electrostatic interaction is a common and relatively mild process suitable for mucosal 
drug delivery.  
 
Alginic acid, also called algin or alginate, is an anionic polysaccharide 
distributed widely in the cell walls of brown algae, where it, through binding water, 
forms a viscous gum. In extracted form it absorbs water quickly; it is capable of 
absorbing 200-300 times its own weight in water (Roew and Raymond, 2009). Its 
colour ranges from white to yellowish-brown. It is sold in filamentous, granular or 
powdered forms. Alginate is extracted for commercial purposes from various species 
of kelp, or brown algae including Laminaria hyperborean, Ascophyllum nodosum, 
and Macrocysis pyrifera (Smidsrod and Skjak-Braek, 1990). Within the kelp species, 
alginate is found in the intracellular matrix where it constitutes up to 40% of the dry 
weight. The alginate forms mixed slats with various cations naturally found in sea 
water including Mg
2+
, Ca
2+
, Sr
2+
, Ba
2+
, and Na
+
, and the native species is usually 
found as an insoluble Ca
2+
 cross-linked gel (Sutherland, 1991). This alginate as it has 
ability to form a gel in the presence of divalent cations such as calcium. This gel 
shrinks at acidic pH and erodes at alkaline pH. Therefore, it can be used effectively to 
deliver drug to the intestine (Desai et al., 2009).  
The natural polymers like alginate have been used to develop drug delivery 
system for entrapping the delivering drugs orally (Ain et al., 2003). When alginate is 
harvested, the algae is mechanically collected and dried, then the material is milled 
and treated with dilute acid to remove and dissociate neutral homopolysaccharides 
and exchange the alkaline earth cations with H
+
 before the alginate in extracted. With 
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the addition of sodium carbonate below pH 10, the alginate is then converted to the 
soluble sodium salt from the insoluble protonated form and can be further purified 
and sold in salt or acid form (Sutherland, 1991). Due to the natural extraction process 
used to obtain alginate, there are many impurities that may potentially contaminate 
the product. These impurities include heavy metals, endotoxin, proteins, other 
carbohydrates, and polyphenals contained in the kelp (Smidsrod and Skjak-Braek, 
1973). When harvested alginate is used in food and drug industries small traces of 
theses impurities are acceptable, but when it comes to medicinal applications they 
must be removed. New methods of harvesting and purification have been developed 
to address the problem of contamination, and now pharmaceutical grade alginate is 
available from numerous chemical manufactures. Uncoated calcium alginate gel 
beads are destabilised when chelators such as phosphate, lactate or citrate or non-
gelling cations like sodium or magnesium ions are present (Smidsrod and Skjas, 
1990).  
Therapeutic proteins and oral drug delivery system 
Most therapeutic peptides and proteins are hydrophilic, with Log P values <0. 
Thus, they would not be expected to follow the trans-cellular route of absorption 
through passive diffusion (Camenisch et al., 1998). The dimensions of the para-
cellular space lie between 10 and 30–50A°, and the para-cellular route is not an option 
for macromolecular absorption because it is restricted to relatively small hydrophilic 
molecules that can fit in these spaces (Rubas, et al., 1996). In the case of one of the 
most widely prescribed protein drugs, insulin, evidence of a para-cellular route of 
absorption was not shown by either morphocytochemical or biochemical analyses 
(Bendayan et al., 1994). It was demonstrated that insulin adsorbed to the apical 
membrane and was internalized by certain types of endocytosis (Agarwal and Khan, 
2001). Some proteins have been shown to be actively transported across the epithelial 
lining of the small intestine in membrane-bound vesicles after binding to cell-surface 
receptors or binding sites (Bastian et al., 1999).  
There are some interesting evidences that significant amount of protein and 
peptide (i.e. enough to induce pharmacological effect) can be absorbed if these are 
protected from proteolytic degradation from proteolytic enzymes in GI tract (Ward et 
al., 2000). There are two possibilities to overcome the problems associated with the 
drug delivery in the GI tract the first one is the functional modification of the 
intestinal epithelial cell physiology or proteolytic enzyme activity and the second one 
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is the protection of the protein or peptide drugs from adverse conditions of GI tract by 
encapsulating drugs with stabilising agents using pharmacological technologies. A 
great number of publications reports encapsulation of various molecules such as drugs 
(Yu et al., 2009), proteins (Morishita et al., 1992; Pan et al., 2002 and Wu et al., 
2011) etc.  
A delivery system with a release profile that is characterized by a time period 
of no release (lag time) followed by a rapid and complete drug release (pulse release) 
can be called as an ideal pulsatile drug delivery system. In other words, it is required 
that a drug should not be released at all during the initial phase of dosage form 
administration (Saigal et al., 2009). Lag time is defined as the time between when a 
dosage form is placed into an aqueous environment and the time at which the active  
ingredient begins to get released from the dosage form. While not meant to be 
limiting, one way to measure lag time is to determine the amount of time before 5% 
of the drug dose is released from a device when the device is exposed to an 
appropriate aqueous environment in a United States Pharmacopoeia paddle stirring 
dissolution apparatus (USP 2) operated at 50 rpm. A lag time of at least 0.5h or longer 
is considered to be important while a lag time of less than 0.5 h is of little 
significance. Lag times of more than 4h are desired for delivery of drug into the lower 
portion of the small intestine while lag times of between 0.5h and 4h are desirable in 
drug delivery in the upper regions of the gastrointestinal tract (Ayres, 2004). 
In the exploration of oral controlled release drug administration, one 
encounters three areas of potential challenge (Chien, 1992). 
1. Development of a drug delivery system: To develop a viable oral controlled release 
drug delivery system capable of delivering a drug at a therapeutically effective rate to 
a desirable site for duration required for optimal treatment. 
2. Modulation of gastro intestinal transit time: To modulate the GI transit time so that 
the drug delivery system developed can be transported to a target site or to the vicinity 
of an absorption site and reside there for prolonged period of time to maximize the 
delivery of a drug dose. 
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3. Minimization of hepatic first pass elimination: If the drug to be delivered is 
subjected to extensive hepatic first pass elimination, preventive measures should be 
devised to either bypass or minimize the extent of hepatic metabolic effect.  
Anatomy and Physiology of the gastrointestinal tract and drug delivery 
Systems used for the delivery of therapeutic agents via the oral route must be 
designed conscious of the physiology of the gastrointestinal tract. The anatomy and 
physiology of route of administration may dictate many of the requirements for the 
systems. For example, the device must be able to withstand the saliva, as saliva 
contains digestive enzymes and other reagents for breaking down whatever is placed 
in the mouth. The stomach, the main digestive organ of the body, contains many 
digestive enzymes and very low pH. The pH of the stomach has been measured from 
1.4 to 2.1.This harsh environment causes the destruction and denaturation of proteins 
without protection. The pH of the stomach changes when food is present increasing to 
nearly 4.0(Dressman et al., 1990). 
Once through the harsh conditions of the stomach a device reaches the small 
intestine, which is divided into three regions. The first region, closest to the stomach, 
is the duodenum, followed by the jejunum and ileum. The duodenum is about 10 
inches in length, composes 5% of small intestine and jejunum composes 40% of the 
length of the small intestine. The entire length of the small intestine is 5 meter and 
residence time within the organ typically ranges from 2-4 h. 
Microparticles smaller than 10 μm are transported to the payer’s patches of the 
gut associated lymphoid tissue (GALT) (Eldridge et al.,1990; Smith et al.,1995 and 
Jani et al.,1992). The GALT is represented by the Payer’s patches (PPs), the appendix 
and small solitary lymphoid nodules. The dome regions of the PPs contains 
lymphocytes, macrophages and some plasma cells and is covered by the follicle 
associated epithelium which is specialised in the uptake of antigens from foods. The 
cells responsible for the actual uptake of viruses, bacteria, toxins and microparticles 
smaller than 10 μm are the microfold cells (M-cells) (Lydyard and Grossi, 1998; 
Eldridge et al., 1990). These M cells differ in morphology from absorptive cells by 
their short microvilli, small cytoplasmic vesicles and few lysosomes.Fig.3 gives an 
overall idea about GIT and protein digesting enzymes involved in GIT.  
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Fig.3. Human gastrointestinal tract (Lehninger principles of Biochemistry, 2008). 
The lining of the small intestine are composed of the serous, muscular, areolar, 
and mucous layers. Only the mucous and areolar layers are the important layers with 
respect to drug delivery. Transport of the nutrients into the body occurs through the 
mucious cell layer and into the areolar layer where the nutrients are taken into the 
blood stream. In the mucosal layer, there are cell layers that stick out of it and into the 
open areas of the duodenum. 
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Fig.4. Schematic representation of the follicle associated epithelium. M-cells 
(M) are located in between the epithelial cells in the lymphoid associated epithelium. 
M-cells are the entrance port to the Peyer’s patches (PP) and efficiently take up 
microparticles smaller than 10 μm. B, B-lymphocytes; E, epithelial cells (Lubben et 
al., 2001). 
Table1. Gastrointestinal Tract: Physical Dimensions and Dynamics (Chien, 1992). 
Region Surface area(m
2
) Length(m) Transit time 
Fluid Digestive solid 
GIT 200 ---- ---- ---- 
Stomach 0.1-0.2 ---- 50 min 8 h 
Small intestine 100-4500 3.0 2-6 h 4-9 h 
Large intestine 0.5-1.0 1.5 2-6 h 3h -3days 
 
Model Protein Bovine Serum Albumin 
Bovine serum albumin has been reported as a model protein by so many 
authors for protein drug delivery (Xing et al., 2008; Takka and Gruel, 2010; Lemma 
et al, 2006 and Nayar et al., 2010). It has been well characterized and the physical 
properties of this protein are well known thus it can be used as a model protein. The  
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solution stability of BSA is very good (especially if the solutions are stored as frozen 
aliquots).  In fact, albumins are frequently used as stabilizers for other solubilized 
proteins (e.g. labile enzymes).  However, albumin is readily coagulated by heat 
(Lewis, 1993). When heated to 50°C or above, albumin quite rapidly forms 
hydrophobic aggregates which do not revert to monomers upon cooling (Hi-media 
data).At somewhat lower temperatures aggregation is also expected to occur, but at 
relatively slower rates. The full-length BSA (bovine serum albumin) precursor protein 
is 607 amino acids in length. An N-terminal 18-residue signal peptide is cut off from 
the precursor protein upon secretion; hence the initial protein product contains 589 
amino acid residues. An additional 4 amino acids is cleaved to yield the mature BSA 
protein that contains 585 amino acids (Wright and Thompson, 1975). 
Table 2.Basic data about bovine serum albumin fraction-V 
Peptide Position Length MW 
Full length 
precursor 
1 – 607 607 69,324 
Signal peptide 1 – 18 18 2,107 
Propeptide 19 – 22 4 478 
Mature protein 23 – 607 585 66,776 
Physical properties of BSA: 
 Number of amino acid residues: 585 
 Molecular weight: 66,776 Da 
 Isoelectric point in water at 25 °C: 4.8 
 Extinction coefficient of 43,824 M−1cm−1 at 279 nm 
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                                                                                                                     OBJECTIVES 
 
1. First objective is to formulate a cost effective and biocompatible microparticle based 
oral drug delivery system using natural polymers like alginate and chitosan to 
overcome the GIT barriers for the delivery of proteinaceous drugs effectively. 
 
2. Chitosan and alginates are the naturally occurring substances with biodegradable and 
non-toxic properties. Only Chitosan microparticles/nanoparticles as a drug delivery 
system are not much efficient due to their lesser stability to gastrointestinal tract 
barriers. Therefore, the second objective is to maintain and enhance the stability of the 
drug delivery system of chitosan microparticles by coating with alginate. 
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                                                                                                    PLANS OF WORK 
 
 
Preparation of chitosan microparticles 
   
 
Loading bovine serum albumin (BSA) to chitosan microparticles 
 
 
          Calculation of LC (Loading efficiency) using BCA protein estimation method 
 
 
Preparation of alginate coated chitosan microparticles 
 
 
Measurement of particle size and zeta potential by zeta sizer 
 
 
Morphological characterization by using scanning electron microscope (SEM) 
 
 
                                            Study of in-vitro release of protein 
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                                                            MATERIALS  AND METHODS 
 
MATERIALS 
 Chitosan(Sigma-Aldrich) 
 Sodium alginate(Sigma- Aldrich)  
 Bovine serum albumin fraction –V(Hi-Media)  
 Sodium tripolyphosphate(Sigma-Aldrich)  
 Calcium chloride 
 BCA™ protein estimation kit (Thermo Scientific ) 
 Ultrapure water from Milli-Q water system. 
 Acetic acid 
EQUIPMENTS 
 Stratos low-temperature high-speed centrifuge(Thermo, Germany) 
 Freeze Dryer 
 Magnetic stirrer 
 Sonicator 
 Zeta sizer (Malvern) 
 Scanning electron microscope 
 Electrophoretic apparatus 
 Gel documentation system 
 Spectrophotometer 
 SDS-PAGE apparatus 
 Gel documentation system 
METHODS 
Preparation of chitosan microparticles 
 Chitosan microparticles were prepared by the ionic gelation of chitosan solution with 
anionic sodium tripolyphosphate. 
 First, chitosan was dissolved in 1% and 2%(v/v) acetic acid aqueous solution at  
different concentrations i.e.( 2.5,3.0,4.0,5.0,10.0) mg/ml. 
 Then, TPP was dissolved in distilled water at the concentration of 6mg/ml. 
Subsequently, 5 ml of TPP solution was added drop wisely into 20 ml of  
chitosan solution of all concentration. Now chitosan colloid microparticles were formed 
spontaneously under mild agitation at room temperature on a magnetic stirrer. 
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 After 15-20 minutes, chitosan colloid microparticles were centrifuged at 10,000 rpm 
for 15 min. Then, the supernatant was discarded and the deposit was re-dispersed in 
distilled water for further use. 
 Colloid chitosan microparticles were re-dispersed in 25ml of distilled water under 
continuous ultrasonication to disaggregate the chitosan microparticles. For each 
formulation ultrasonication was done for 10 minutes. 
Loading bovine serum albumin fraction-V (BSA-V) to chitosan microparticles and 
calculation of loading efficiency by BCA protein estimation method. 
 
 The loading procedure was performed by incubating different concentrations of BSA-
V (1.0, 2.0,4.0,8.0)mg/ml with chitosan microparticles under mild agitation at room 
temperature for 15 min.  
 Loading efficiency (LE) of BSA-V on chitosan microparticles were detected in an 
indirect way by determining the free BSA-V remained in the supernatant after the 
performance of centrifuge, and the method was shown as following.  
 One millilitre of BSA loaded chitosan microparticles suspension was centrifuged at 
14,000 rpm for 20 min and the amount of BSA in the supernatant was measured by 
BCA™ kit using a standard curve formulated through spectrophotometer. 
 The supernatant of blank chitosan microparticles was adopted as the blank to correct 
the absorbance reading value of the BSA-loaded chitosan microparticles. The 
corrected optical density (OD) value was then used to calculate the concentration of 
BSA in the supernatant. 
Preparation of alginate coated chitosan microparticles 
 Alginate microparticles were prepared by dissolving sodium alginate in millli-Q 
water with mild agitation at room temperature. 
 Then, alginate microparticles were dispersed into calcium chloride (CaCl2) 
aqueous solution (pH = 7.0) at concentration of 0.5mM/litre. 
 BSA-V loaded chitosan microparticles suspensions with different pH value were 
added drop wisely into sodium alginate solution containing calcium chloride of 
different pH value at different concentration (5.0 and 10.0) mg/ml under mild 
agitation for 10 min.  
 Then the suspension was centrifuged at 3,500 rpm for 5 min, and the supernatant 
was discarded. (Two stage procedure). 
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Fig.5 Schematic representation of method used in preparation of alginate coated 
chitosan microparticles. 
                       
 
Loading efficiency (LE %) was calculated by using above formula in which 
supernatant was considered for estimation of protein specrophotometrically.    
 
 
Morphological characterization 
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Colloidal microparticles were first lyophilized for 24 hours. Then 
morphological characteristics of microparticles were examined by scanning electron 
microscope (SEM). For SEM, a specimen is normally required to be completely dry, 
since the specimen chamber is at high vacuum. Microparticles were sputtered with 
gold and maintained at room temperature for complete dryness before the observation. 
 
In vitro release and checking of protein degradation by SDS-PAGE 
 
After loading the protein (BSA) to the microparticles in vitro release was 
studied by using PBS (phosphate saline buffer) pH 7.4. One milliliter of 
microparticles suspension was first centrifuged and the deposit was incubated in 1 ml 
of phosphate buffer saline (PBS, pH7.4) in eppendorf tube (EP tube). Then, the EP 
tube was placed in an air shaker bath at 100 rpm/min (at 37°C) for in vitro release. At 
scheduled time, samples were centrifuged at 14,000 rpm for 20 min and the 
supernatant was replaced with fresh PBS (previously warmed to 37°C). The amount 
of BSA presented in the supernatant was determined by BCA™ kit using 
spectrophotometer. Then protein degradation was checked by SDS-PAGE(sodium 
dodecyl sulphate polyacrylamide gel electrophoresis) method in which release of 
protein was done in pH 2.0 by using HCl (hydrochloric acid ) for 2 hours (37
o
C) then 
sample was centrifuged at 14,000 rpm for 20 minutes and the supernatant was 
replaced with fresh PBS (previously warmed to 37°C). Schematic diagram of the 
release study is given in fig.6 below. 
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Particles containing BSA (1ml) centrifuged  
at 14,000 rpm for 20 minutes in eppendorf                      PBS (pH 7.4) 
tube and deposit was obtained                                            (1 ml)                                                                               
 
 
 
                                           Deposit with 1ml PBS was incubated  
                                      in incubator shaker  at 37
o
C with 100 rpm 
                                                                                        (After specific interval) 
                                                                                    
                                                   Samples were removed  
                                          and again centrifuged at 14000 rpm  
          For 20 minutes 
 
               
                                                Deposit                                                  Supernatant 
                                                       +        
                                         Fresh PBS 1 ml   
                 
 
 
                                Kept in incubator                                       Estimation for released 
                               Shaker for further studies                           protein spectrophotometrically 
                                  (37
o
c, 100rpm)                                           
 
Fig.6 Schematic representation of release study of BSA from Alginate coated chitosan 
microparticles. 
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                                                                                 RESULTS AND DISCUSSIONS 
In this research paper we have prepared alginate coated chitosan 
microparticles by two stage procedure in which first chitosan microparticles were 
prepared using ionic gelation technique (Hejazi and Amiji, 2003) by addition of 
sodium tripolyphosphate as a precipitating agent. Then BSA with isoelectric point 
(PI) of 4.8 was negatively charged when pH >4.8, which could easily absorb cationic 
chitosan microparticles at aqueous solution (pH 7.0) via electrostatic interactions. 
Thus BSA was used as a model protein for evaluation of the properties of the alginate 
coated chitosan microparticles. Simultaneously alginate microparticles were prepared 
by dissolving in milli-Q water and then 0.5 mM Calcium chloride solution was added 
to it in which calcium ion acts as a cross linking agent to strengthen and stabilize the 
particle . This completes the first stage of the procedure. In the second stage Alginate 
microparticles were added drop wisely on to the chitosan microparticles loaded with 
BSA protein. 
Blank chitosan microparticles analysis  
Sample 1250,130,140,150,1100,2250,230,240,250,2100 ( see appendices) are 
the blank chitosan microparticles without loading of BSA were analysed in the zeta 
sizer to evaluate particle size, PDI and zeta potential by taking refractive index of 
chitosan 1.523.Some of the zeta sizer analysis graphs were given in fig 8-9.It was 
found that with increase in chitosan concentration the particle size increases. The 
particle size increased from 126.4nm to1321nm when chitosan concentration was 
increased from 2.5mg/ml to 10 mg/ml in case where chitosan was dissolved in 1% 
acetic acid (table 4). Similarly the particle size increased from 126.0 nm to 1266 nm 
when chitosan concentration was increased from 2.5mg/ml to 10 mg/ml in the case 
where chitosan was dissolved in 2% acetic acid as given in fig. 7 and table 5.Thus it 
can be also concluded that more the concentration of acetic acid less will be the 
particle size (but to a smaller extent), probably because chitosan were dissolved finely 
in more concentrated acetic acid. Respective PDI values of the formulations were 
evaluated.Polydispersity index (PDI), a term in polymer chemistry referring to the 
molecular weight distribution of polymers.  
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Fig 7. Effect of different concentratios of chitosan (dissolved in 2% acetic acid) on mean 
particle size. 
Zeta potential is a scientific term for electro-kinetic potential (McNaught and 
Wilkinson, 1997) develops at the surface of the colloidal particles.in fig 9 shows the 
zeta potential readings and other distributions like voltage and current etc. The 
significance of zeta potential is that its value can be related to the stability of colloidal 
dispersions. The zeta potential indicates the degree of repulsion between adjacent, 
similarly charged particles in dispersion. For molecules and particles that are small 
enough, a high zeta potential will confer stability, i.e., the solution or dispersion will 
resist aggregation. When the potential is low, attraction exceeds repulsion and the 
dispersion will break and flocculate. So, colloids with high zeta potential (negative or 
positive) are electrically stabilized while colloids with low zeta potentials tend 
to coagulate or flocculate as outlined in the table 3. 
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Fig.8 Zeta sizer analysis data with zeta potential of 5mg/ml 
chitosan.  
Fig. 9 Statistical analysis of particle size distribution of chitosan 5mg/ml. 
Zeta potential [mV] Stability behaviour of the colloid 
From 0 to ±5, Rapid coagulation or flocculation 
From ±10 to ±30 Incipient instability 
From ±30 to ±40 Moderate stability 
From ±40 to ±60 Good stability 
More than ±61 Excellent stability 
 
Table 3.Zeta potential and colloid stability behaviours derived from Zeta Potential of 
Colloids in Water and Waste Water", ASTM Standard D 4187-82, American Society for 
Testing and Materials, 1985. 
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Zeta potential of maximum samples were found to be from +30 to 
+60(samples loaded with 1mg/ml and 2mg/ml BSA) i.e. chitosan colloid particles 
loaded with 1mg/ml and 2mg/ml BSA were having moderate to good stability. On the 
other hand chitosan colloid particles loaded with 4mg/ml and 8mg/ml BSA, zeta 
potential were varies from +10 to +30 (maximum case) i.e. chitosan colloid particles 
loaded with 4mg/ml and 8mg/ml BSA were having incipient stability. In some case of 
chitosan microparticles loaded with 8mg/ml BSA, zeta potential was less than +10 
means sample were having  rapid coagulation or flocculation properties.   
 
Procedure of BSA loading and Effect of BSA concentration on chitosan 
microparticles 
The chitosan microparticles were incubated in aqueous solution with different 
BSA concentrations at a relatively mild condition to obtain suitable loading efficiency 
LE).Cationic microparticles can easily absorb anionic protein or DNA via 
electrostatic interaction (Illum et al., 2001; Cui and Mumper, 2001).Cationic chitosan 
microparticles prepared in this work had a potent capacity to absorb the model anionic 
protein (BSA) in aqueous solution (pH 7.0) via electrostatic interaction. The obtained 
chitosan microparticles at different concentrations were adopted to evaluate particle 
size, zeta potential, loading efficiency. The loading efficiency was calculated using 
BCA standard graph for BSA protein by using spectrophotometer (fig 10). 
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Fig 10 .BCA standard graph using BCA
TM
 kit
. 
 
 As presented in Table 4 and 5 effect of BSA concentration on the properties 
of chitosan microparticles were investigated. The mean diameter of chitosan 
microparticles increased accompanied with decrease in zeta potential when BSA 
concentration increased from 1 mg/ml to 8 mg/ml. This might be attributed to the fact 
that negatively charged BSA absorbed onto chitosan microparticles and neutralized 
part of zeta potential of chitosan microparticles resulted in increase of particle size 
and decrease of zeta potential (Xu and Du, 2003).It was seen that when BSA 
concentration was less than 2mg/ml or 2mg/ml then the loading efficiency was more 
as compared to other formulations with BSA concentration 4mg/ml or 8 mg/ml. This 
interesting phenomenon might be attributed to the saturated absorption was achieved 
as BSA concentration at about 2 mg/ml, the more addition of BSA was seldom 
adsorbed onto chitosan microparticles which leaded to the great decrease in loading 
efficiency (Xing et al., 2008).The loading efficiency of 141, 151, 1101, 1102, 251, 
252, 2101 and 2102 were found to be more than 60% while sample 241 was found to 
be 59%(table 2 and 3).The mean particle size of the formulation 1101, 1102.2101 and 
2102 were more than 1350 nm. Thus, these formulations were not taken into account 
because of their large particle size. Here in this article formulation with chitosan 
4mg/ml, 5mg/ml were taken as standardised particles to coat with alginate 
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microparticles. A comparative graphical presentation of the variation in loading 
efficiency due to change in concentrations of different parameters like BSA 
concentration, Chitosan concentration and also to small extent the acetic acid 
concentration is given in fig 11. 
 
 
 
Fig 11. Effect of different BSA and chitosan concentration on loading efficiency (LE).  
 
 
 
 
 
 
 
     141 151                 142 152                241 251              241  252 
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Table 4.Formulations of chitosan microparticles with 1% acetic acid and their mean particle size, 
PDI and zeta potential. 
Sl.No Sample 
name 
 
pH 
Mean 
particle 
size 
PDI 
 
Zeta 
potential 
 
Loading 
efficiency 
(%) 
1. 1250 3.48 126.4 0.507 +43.9 --- 
2. 1251 -- 215.0 0.337 +33.3 44.0 
3. 1252 -- 243.8 0.410 +24.5 32.0 
4. 1254 -- 256.1 0.370 +14.2 24.0 
5. 1258 -- 289.6 0.432 +9.4 17.0 
6. 130 3.62 174.1 0.383 +46.2 --- 
7. 131  259.8 0.447 +35.5 47.0 
8. 132 -- 294.5 0.387 +26.6 35.0 
9. 134 -- 327.0 0.471 +16.5 26.0 
10. 138 -- 353.9 0.337 +10.9 18.0 
11. 140 3.82 236.5 0.468 +53.5 --- 
12. 141 -- 309.4 0.337 +36.1 64.0 
13. 142 -- 326.7 0.391 +28.5 52.0 
14. 144 -- 347.3 0.379 +17.3 40.0 
15. 148 -- 379.9 0.399 +11.1 29.0 
16. 150 3.97 316.4 0.476 +45.4 --- 
17. 151 -- 402.3 0.447 +36.8 69.0 
18. 152 -- 419.0 0.509 +29.4 56.0 
19. 154 -- 443.4 0.534 +20.7 42.0 
20. 158 -- 478.7 0.584 +11.9 31.0 
21. 1100 4.19 1321.0 0.802 +54.9 --- 
22. 1101 -- 1357.0 0.900 +43.5 66.0 
23. 1102 -- 1378.1 0.943 +34.9 61.0 
24. 1104 -- 1398.5 0.954 +31.2 50.0 
25. 1108 -- 1402.3 0.977 +23.9 44.0 
 
--Not checked 
---No loading of protein 
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Table 5.Formulations of chitosan microparticles with 2% acetic acid and their  
Mean particle size, PDI and zeta potential. 
Sl.No Sample 
name 
 
pH 
Mean 
particle 
size 
PDI 
 
Zeta 
potential 
 
Loading 
efficiency 
(%) 
26. 2250 3.34 126.0 0.455 +40.2 --- 
27. 2251 -- 213.6 0.339 +34.3 48.0 
28. 2252 -- 243.8 0.440 +23.6 30.0 
29. 2254 -- 256.9 0.370 +14.4 25.0 
30. 2258 -- 283.4 0.439 +9.9 19.0 
31. 230 3.40 170.9 0.445 +46.2 --- 
32. 231 -- 269.3 0.497 +35.8 50.0 
33. 232 -- 299.8 0.387 +26.0 38.0 
34. 234 -- 329.1 0.481 +16.5 30.0 
35. 238 -- 358.9 0.387 +10.9 22.0 
36. 240 3.49 219.9 0.456 +48.0 --- 
37. 241 -- 309.9 0.357 +34.9 59.0 
38. 242 -- 336.7 0.399 +28.8 52.0 
39. 244 -- 348.8 0.379 +19.8 41.0 
40. 248 -- 372.2 0.390 +11.9 29.0 
41. 250 3.55 315.8 0.384 +45.4 --- 
42. 251 -- 400.3 0.497 +34.8 67.0 
43. 252 -- 419.8 0.589 +29.4 60.0 
44. 254 -- 448.9 0.584 +20.2 42.0 
45. 258 -- 473.9 0.584 +13.9 31.0 
46. 2100 3.81 1266.0 0.905 +54.2 --- 
47. 2101 -- 1352.0 0.899 +48.5 66.0 
48. 2102 -- 1373.1 0.948 +34.9 61.0 
49. 2104 -- 1390.8 0.959 +34.2 49.0 
50. 2108 -- 1400.8 0.979 +23.9 41.0 
 
--Not checked 
---No loading of protein 
Blank Alginate microparticles analysis  
Two samples of alginate microparticles having 5mg/ml and 10 mg/ml 
concentrations were prepared by dissolving Alginate in milli-Q water with mild 
agitation by magnetic stirrer in room temperature and then alginate microparticles 
were dispersed into calcium chloride (CaCl2) aqueous solution (pH = 7.0) at 
concentration of 0.5mM/litre. Particles were analysed in zeta sizer to evaluate particle 
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size, PDI and zeta potential as given in table 6  and fig 12-13.As alginate is anionic 
thus zeta potential was found negative. For both the concentrations zeta potentials 
found to be more than -63 i.e. Alginate microparticles were showing excellent 
stability. The particle size of 5mg/ml and 10 mg/ml alginate solution were 1147nm 
and 3914 nm respectively. Due to larger particle size 10 mg/ml alginate solution were 
not taken into consideration for further studies to formulate alginate coated chitosan 
microparticles formation. 
 
Table 6.Formulations of alginate microparticles with mean particle size, PDI and zeta 
potential. 
Sl 
No. 
Concentration of 
Alginate mg/ml 
Mean 
particle size 
in nm 
PDI Zeta potential( mV) 
1. 5.0 1157.0 0.446 -63.1 
2. 10.0 3914.0 0.683 -63.3 
 
 
 
 
Fig. 12.Zeta potential distribution of alginate microparticles. 
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     Fig 13 Particle size distribution of alginate 5mg/ml microparticles. 
 
Alginate coated BSA loaded chitosan microparticles analysis 
Due to the electrostatic interaction between the positively charged -NH3 
+
 of 
chitosan microparticles and negatively charged -COO
-
 of alginate, cationic BSA-
loaded chitosan microparticles could be easily modified with anionic alginate in 
aqueous solution via electrostatic interaction (Fan et al., 2006). However, the addition 
of anionic alginate to cationic BSA loaded chitosan microparticles would replace 
some of BSA absorption on the chitosan microparticles due to the competitive 
electronic interaction (Borges et al., 2005). Alginate were coated to the BSA loaded 
chitosan microparticles having higher stability and greater LE like samples 
141,142,151,152,241,242,251 and 252.After coating of alginate 5mg/ml to all the 
samples the zeta potential evaluated between -20 to -30 which shown incipient 
stability properties according to table 7.The mean particle size of the formulations 
1415, 1425, 2415and 2425 were found to be in between 1400 nm to 1425 nm while 
formulations 1515, 1525, 2515and 2525 were having particle size in between 1547nm 
to 1570 nm.A comparative account of particle size of different alginate coated 
chitosan microparticles are given in fig 14- 16 .The zeta potential value of the 
different alginate coated chitosan microparticles were in between -20 to -30 showing 
incipient stability. 
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Table 7.Formulations of alginate coated chitosan microparticles with mean particle size, 
PDI and zeta potential. 
 
Sample 
code  
Mean 
particle 
size 
 
PDI 
 
Zeta 
potential 
 
After 
coating 
Alginate 
5 mg/ml 
Sample 
Mean 
particle 
size 
 
PDI 
 
Zeta 
potential 
 
141 309.4 0.337 +36.1 1415 1402.5 0.409 -26.7 
142 326.7 0.391 +28.5 1425 1415.7 0.468 -22.5 
151 402.3 0.447 +36.8 1515 1554.0 0.497 -26.1 
152 419.0 0.509 +29.4 1525 1567.9 0.543 -21.4 
241 309.9 0.357 +34.9 2415 1405.9 0.413 -27.8 
242 336.7 0.399 +28.8 2425 1422.7 0.439 -23.9 
251 400.3 0.497 +34.8 2515 1547.2 0.556 -27.3 
252 419.8 0.589 +29.4 2525 1569.0 0.599 -22.7 
 
 
 
 
Fig14.Comparative analysis of alginate coated chitosan microparticles where chitosan 
concentration was 4mg/ml and different BSA was used.   
 
 
      1415            1425             2415            2425 
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Fig15.Comparative analysis of alginate coated chitosan microparticles where chitosan 
concentration was 5mg/ml and different BSA was used.   
 
Fig16.Comparative analysis of alginate coated chitosan microparticles where chitosan 
concentration was 4mg/ml and 5mg/ml with different BSA concentration was used.   
 
 
     1515            1525                   2515                2525  
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In vitro Protein release study 
           The release profiles of BSA from uncoated chitosan and alginate coated 
chitosan microparticles in phosphate buffer (PBS, pH7.4). As depicted in Fig 17-20, 
the initial burst release of BSA from uncoated chitosan microparticles 141,142,151 
and 152 was about 87.5%,87.9%,86.2% and 85.3% respectively  occurred in the first 
0.5 hour, followed by release of 97.1% ,97%,96.9% and 96.5% respectively in 48 
hours. The burst release might be attributed to the fact that BSA macromolecules were 
loosely bound onto chitosan microparticles by ionic interaction which could be easily 
desorbed at ionic environment (Chen et al., 2007). However, alginate modified 
chitosan microparticles could increase the stability of chitosan microparticles in the 
PBS at 37°C which resulted in extended release of BSA, in these formulations like 
1415, 1425, 1515 and 1525 only about 21.1%, 21.2%, 20.9% and 21.2% of BSA 
released in 0.5 hour respectively and 48 h later, there was still about 50% of BSA 
retained in the alginate coated chitosan   microparticles. 
 
 
                  Fig 17. Comparative release study of sample 141 (up) and sample 1415 (down). 
              The total ratio of BSA released from the alginate coated chitosan 
microparticles in 48 h was much less than that observed from uncoated chitosan 
microparticles. The longer release time and slower release rate of BSA from alginate 
coated chitosan microparticles might be explained by that there are strong interaction 
between polymers (chitosan and alginate) and BSA (Coppi  et al.,2001). 
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Fig18.Comparative release study of sample 142 (up) and sample 1425 (down).                           
 
             Fig 19. Comparative release study of sample 151(up) and sample 1515(down). 
 
              
 
           Fig 20.Comparative release study of sample 152(up) and sample 1525(down). 
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           The total ratio of BSA released from the alginate coated chitosan 
microparticles in 48 h was much less than that observed from uncoated chitosan 
microparticles. The longer release time and slower release rate of BSA from alginate 
coated chitosan microparticles might be explained by that there are strong interaction 
between polymers (chitosan and alginate) and BSA (Coppi  et al., 2001). 
Additionally, the presence of alginate layer could slow down the diffusion of BSA 
from the system which also prolong the release time of BSA from system. But, due to 
both the degradation and erosion of matrix, the BSA might be released from the 
alginate/BSA/chitosan formulation in an extended profile (Anal et al., 2003). This 
release behaviour studies indicated that coating of alginate onto chitosan 
microparticles could improve the stability of chitosan microparticles in PBS and 
modify the release behaviour of BSA from these alginate coated chitosan 
microparticles. 
 
Detection of Acidic degradation protection by SDS-PAGE 
 
In this paper, I have tried to design an oral drug delivery system for protein. 
As we know, pH value of gastric fluid is approximately 2 which will destroy the 
integrity and structure of antigens (protein, DNA, etc.) after the oral administration 
without any protection (Xing et al., 2008). Thus, it is very important to develop a 
protein carrier based on chitosan and alginate that can effectively avoid the acidic 
degradation of encapsulated protein before it reached the target site. Here, BSA 
released from uncoated and alginate coated chitosan microparticles under acidic 
medium (pH2.0) and PBS medium (pH7.4) was analysed by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE).  
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Fig. 21.SDS-PAGE for BSA loaded alginate chitosan microparticles for analysis 
of protein degradation. 
 
                   
Fig. 22. SDS-PAGE for BSA loaded uncoated chitosan microparticles for 
analysis of protein degradation. 
 
 
 Lane 1: 151 in 0.01M HCl  
 
Lane 2: 252 in 0.01M HCl  
 
Lane 3: 152 in 0.01M HCl  
 
Lane 4:251 in PBS for 24 hr  
 
Lane 5:151 in PBS for 24 hr  
 
Lane 6:252 in PBS for 24 hr  
 
Lane 7:152 in PBS for 24 hr  
 
Lane 8: Control BSA 2mg/ml  
 
Lane 9: Control BSA 4mg/ml 
  1       2      3       4        5      6      7       8       9  
 Lane 1: 1515 in 0.01M HCl  
 
Lane 2: 2525 in 0.01M HCl  
 
Lane 3: 1525 in 0.01M HCl  
 
Lane 4:2515 in 0.01M HCl  
 
Lane 5:1515 in PBS for 24 hr  
 
Lane 6:2525in PBS for 24 hr  
 
Lane 7:1525 in PBS for 24 hr  
 
Lane 8: Control BSA 2mg/ml 
  
Lane 9: Control BSA 4mg/ml 
  1       2      3       4        5      6      7         8       9 
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Fig. 23. SDS-PAGE for BSA loaded uncoated chitosan and alginate coated 
chitosan microparticles for analysis of protein degradation. 
According to Fig.23, BSA 2mg/ml and 4mg/ml (Lane 8 and Lane 9 
respectively) were taken as control and the different formulations of BSA loaded 
alginate chitosan microparticles were incubated with PBS (pH7.4) for 24 h exhibited a 
clear band (Lane 4, Lane 5, Lane 6 and Lane 7) at about at same distance as control 
(Lane 8 and Lane 9). However, BSA pre-treated with 0.01 M HCl for 2 hours then 
incubated with PBS for 24 hours had a faint band (Lane 1 ,Lane 2 and Lane 3)at same 
distance as control (Lane 8 and Lane 9) which indicated the serious degradation or 
hydrolysis of BSA in acidic medium. The SDS-PAGE gel banding patterns of BSA 
released from uncoated and alginate coated chitosan microparticles with HCl (pH2.0) 
pre-treatment for 2 h and then sustained release in PBS for 24 h are shown in Lane 1 
and Lane 2, respectively. It is seen that BSA from uncoated chitosan microparticles 
had a very weak band at control (Lane 1) which indicated that the BSA underwent 
hydrolysis/degradation in spite of presence of chitosan microparticles (pH2.0).  
 
 
 1       2      3       4      5      6        7         8        9  
 
Lane 1: 151 in 0.01M HCl  
 
Lane 2: 252 in 0.01M HCl  
 
Lane 3: 152 in 0.01M HCl  
 
Lane 4:1515 in 0.01M HCl  
 
Lane 5: 1525 in 0.01M HCl  
 
Lane 6: 2525 in 0.01M HCl  
 
Lane 7: 1525 in PBS for 24 hr  
 
Lane 8: Control BSA 2mg/ml  
 
Lane 9: Control BSA 4mg/ml 
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Meanwhile, we also observed the flocculent precipitate of system with the addition of 
sodium hydrate to BSA loaded chitosan microparticles which implied the dissolution 
of chitosan microparticles in acidic condition (pH2). However, BSA from alginate 
coated chitosan microparticles had a clear band at about control (Lane 2), which 
implied that alginate coating of chitosan microparticles could effectively protect BSA 
from hydrolysis/degradation at acidic medium for at least 2 h. So, the obtained 
alginate coated chitosan microparticles might be an effective oral protein delivery. 
 
Characterization of chitosan microparticles 
 
The obtained chitosan microparticles and alginate coated BSA loaded 
chitosan microparticles were characterized by SEM and laser diffraction. Two 
typical scanning electron microphotographs BSA loaded chitosan microparticles 
were presented in fig 24 (a) and (b).and shown that some of the particles were 
more than 1μm in diameter. Just similar peaks of particle size were also observed 
in Malvern zeta sizer instrument. Some of the particles were observed as 0.1 μm in 
size but most of the particles were in between 200-600 nm in size were observed. 
It was also observed that some small chitosan microparticles fused into large ones. 
The result detected by Malvern Instrument indicated that the average size of chitosan 
microparticles was about 315 nm (5mg/ml chitosan). 
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(a) 
 
(b) 
Fig.24 (a) and (b) SEM images of BSA loaded chitosan microparticles.  
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                                                                                           CONCLUSION 
 
The prepared alginate coated chitosan microparticles, with mean diameter of about 1.5 μm, 
were suitable for oral administration. Alginate coating onto surface of chitosan microparticles 
could modulate the release behaviour of BSA from alginate coated chitosan microparticles 
and it could effectively protect model protein (BSA) from degradation against acidic medium 
(pH 2) in vitro at least for 2 hours based on the information demonstrated, by SDS-PAGE 
analysis of the protein degradation. Thus, it can be concluded that prepared alginate coated 
chitosan microparticles are cost effective oral drug delivery system that can be used as a 
carrier for proteinaceous drugs. It can effectively release the encapsulated proteinaceous 
drugs and protect its degradation from GIT barriers for a longer period of time. 
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